CIB-L43

CIB-L43 is an orally active TRBP inhibitor (KD = 4.78 nM) and enhances disruption of TRBP-Dicer interactions (IC50 = 2.34 μM) . CIB-L43 suppresses oncogenic miR-21 biosynthesis, increasing PTEN and Smad7 expression and inhibiting AKT and TGF-β signaling, thereby reducing HCC cell proliferation and migration[1].

Product Specifications

CAS Number

[1082942-70-8]

UNSPSC

12352005

Target

Akt; PTEN; TGF-beta/Smad

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.71

Solubility

DMSO : 8.93 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC(C1=C(N=C(C2=CC=C(C=C2)N3CCOCC3)S1)C)=O

Molecular Formula

C15H16N2O3S

Molecular Weight

304.36

References & Citations

[1]Shi H, et al. Design, Synthesis, and Antitumor Activity Evaluation of 2-Phenylthiazole-5-Carboxylic Acid Derivatives Targeting Transactivation Response RNA-Binding Protein 2. J Med Chem. 2025 Jan 9;68 (1) :421-447.